Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Tyulyandina, A."'
Autor:
Valeriy V. Breder, Liudmila G. Zhukova, Larisa V. Bolotina, Irina A. Demidova, Yaroslav A. Zhulikov, Elena V. Lubennikova, David R. Naskhletashvili, Sergey V. Orlov, Rashida V. Orlova, Ilya S. Romanov, Nikita A. Savelov, Ksenia A. Sarantseva, Alexandra S. Tyulyandina, Mikhail Yu. Fedyanin
Publikováno v:
Современная онкология, Vol 25, Iss 3, Pp 295-300 (2023)
NTRK-fusion positive tumors are a rare finding, but targeted therapy demonstrates persistent and sustained systemic and intracranial responses to entrectinib. This resolution proposes algorithms for diagnosing NTRK translocations in various solid tum
Externí odkaz:
https://doaj.org/article/c5b921b0ebf8481e8510cf935262712f
Autor:
A. S. Tyulyandina, E. A. Ulrikh, L. A. Kolomiets, S. E. Krasilnikov, A. G. Kedrova, A. A. Rumyantsev, G. A. Raskin, A. I. Nesterova, M. V. Volkonskiy, O. N. Churuksaeva, A. Yu. Goryainova, V. V. Zhavoronkova, V. N. Dmitriev, S. T. Nazranova, A. V. Shkradyuk, K. S. Volkova, A. I. Arutyunova, S. N. Kunitskaya, L. V. Stepura, T. G. Zolotoreva, E. B. Shakhnovich, E. V. Ponomareva, M. A. Strokova, A. S. Danilova, E. S. Martynova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 4, Pp 138-146 (2023)
Deficient DNA mismatch repair (dMMR) is a rare molecular disorder found in 20-30 % of endometrial tumors. Laboratory identification of dMMR/microsatellite instability (MSI) has a high diagnostic value, since these impairments are considered as biomar
Externí odkaz:
https://doaj.org/article/dd56d4fb73f4467fa248768ea1bf41c3
Autor:
Goh, Jeffrey C.H., Gourley, Charlie, Tan, David S P, Nogueira-Rodrigues, Angélica, Elghazaly, Hesham, Edy Pierre, Marc, Giornelli, Gonzalo, Kim, Byoung-Gie, Morales–Vasquez, Flavia, Tyulyandina, Alexandra
Publikováno v:
In Gynecologic Oncology Reports August 2022 42
Autor:
A. A. Rumyantsev, A. S. Tyulyandina, I. A. Pokataev, E. R. Israelyan, M. Е. Abramov, H. N. Lud, S. A. Tyulyandin
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 77-83 (2022)
Introduction. Olaparib is the only PARP inhibitor approved in Russia for the maintenance therapy for BRCA-positive ovarian cancer after frontline chemotherapy. We conducted a real-world analysis of olaparib efficacy and safety for this indication.Aim
Externí odkaz:
https://doaj.org/article/bfaddd974a224ac8b80f777641cf367f
Autor:
Bourhis, Amélie, Caumont, Charline, Quintin-Roué, Isabelle, Magro, Elsa, Dissaux, Gurvan, Remoué, Annabelle, Le Noac’h, Pierre, Douet-Guilbert, Nathalie, Seizeur, Romuald, Tyulyandina, Alexandra, Schick, Ulrike, Merlio, Jean-Philippe, Marcorelles, Pascale, Cappellen, David, Uguen, Arnaud
Publikováno v:
In Pathology February 2022 54(1):55-62
Publikováno v:
Современная онкология, Vol 23, Iss 4, Pp 638-644 (2021)
Aim. To analyze the data available in the modern literature on the role of repeated cytoreduction in the complex treatment of relapses ovarian cancer (OC). Materials and methods. Sources were searched in the following systems Clinicaltrials.gov, P
Externí odkaz:
https://doaj.org/article/08979316763a4b298907f97943e0a34b
Autor:
Jeffrey C.H. Goh, Charlie Gourley, David S P Tan, Angélica Nogueira-Rodrigues, Hesham Elghazaly, Marc Edy Pierre, Gonzalo Giornelli, Byoung-Gie Kim, Flavia Morales–Vasquez, Alexandra Tyulyandina
Publikováno v:
Gynecologic Oncology Reports, Vol 42, Iss , Pp 101028- (2022)
The incidence and mortality rates of ovarian cancer are increasing globally. Ovarian cancer is diagnosed at an advanced stage in 80% of women. After standard, platinum-based, front-line chemotherapy, poly (ADP-ribose) polymerase (PARP) inhibitors and
Externí odkaz:
https://doaj.org/article/d8b61cfeb7db4d489058ed2b8eecf815
Autor:
T. A. Bogush, M. B. Stenina, E. A. Bogush, V. T. Zarkua, S. A. Kalyuzhny, I. A. Mamichev, A. S. Tyulyandina, S. A. Tyulyandin
Publikováno v:
Антибиотики и Химиотерапия, Vol 63, Iss 1-2, Pp 24-31 (2020)
Platinum-based drugs are widely used in clinical practice. Their efficacy varies widely among patients, which may be due to a disruption of the expression of ERCC1 - excision repair protein. In the prospective study a strictly quantitative analysis o
Externí odkaz:
https://doaj.org/article/1cf2797fa36d45f4b262fec22b867e8f
Autor:
T. A. Bogush, A. S. Popova, E. A. Dudko, E. A. Bogush, A. S. Tyulyandina, S. A. Tyulyandin, M. I. Davydov
Publikováno v:
Антибиотики и Химиотерапия, Vol 60, Iss 3-4, Pp 42-50 (2020)
The review is concerned with the crucial marker of nucleotide excision repair ERCC1 and its contribution to platinum resistance of ovarian cancer. All the variants of the laboratory and clinical ERCC1 assessment in the ovarian cancer tissue (single n
Externí odkaz:
https://doaj.org/article/9388e77230ca4c74a8f6a685601fb976
Autor:
A. A. Rumyantse, A. S. Tyulyandina
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 144-149 (2019)
Ovarian cancer ranks first in the mortality causes pattern of female reproductive cancers in Russia. Treatment of relapsed ovarian cancer remains a significant challenge to practicing oncologists. Introduction of PARP inhibitors in clinical practice
Externí odkaz:
https://doaj.org/article/b7cb9e913efb43a69c53c6968c6db217